BioXcel Therapeutics begins phase 3 trial for acute agitation in Alzheimers patients
BioXcel Therapeutics has announced that the first patient involved in the phase 3 TRANQUILITY 2 study of BXCL501 has received a dose for the acute treatment of agitation in patients with Alzheimer
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!